Tang, Chao-HsiunChao-HsiunTangNewson, Rachel SarahRachel SarahNewsonCHING-HUNG LINChan, Bill Hoi-FongBill Hoi-FongChanWang, Bruce CmBruce CmWangShen, Shih-PeiShih-PeiShenShao, Serena Yu-JuSerena Yu-JuShao2024-12-132024-12-132024https://scholars.lib.ntu.edu.tw/handle/123456789/723842Estimate patient counts, treatment patterns and outcomes of a subset of patients with early breast cancer (EBC) presenting with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive features, who are at high-risk of recurrence, in Taiwan. Data from Taiwan's National Health Insurance Research Database and Taiwan Cancer Registry from 1 January 2011 to 31 December 2020 were analyzed. There were 4500 patients with high-risk EBC (10.4% of all patients with EBC) from 2012 to 2018, with an annual average incidence of 643 that increased over time. Five-year progression was 24.8% in patients with high-risk EBC and 8-year survival was low (69.6%). Patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive high-risk EBC clinical features are an increasing high-risk subset of all patients with EBC.[Box: see text].enHER2-HR+early breast cancerhealth economicshigh-risknode-positive[SDGs]SDG3journal article10.1080/14796694.2024.240728239365110